ReviewFrontiers in bioengineering and biotechnology2023
Systems and synthetic biology-driven engineering of live bacterial therapeutics.
Review in Frontiers in bioengineering and biotechnology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Microbial Systems Enhancing CAR-Based Therapies: A Synthetic Biology Paradigm for Next-Generation Cancer Immunotherapy.Current microbiology · 2025Pooled it
- Alternative treatment of recurrentFrontiers in microbiology · 2024Pooled it
- Advanced gene editing technologies for oncology mechanisms, applications, and clinical implementation.Cancer gene therapy · 2026Review
- Microbiota-Mediator-Host Signaling Networks in Metabolic Syndrome: From Mechanistic Insights to Therapeutic Targeting.Microorganisms · 2026Review
- Targeting the Human Gut Microbiota-Between Conventional Therapy and Precision Genetic Engineering.Nutrients · 2026Review
- From dysbacteriosis to ecological remodeling: A new breakthrough in microbial treatment of inflammatory bowel disease.iScience · 2026Review
- Reprogramming probiotic for uric acid modular degradation and hyperuricemia treatment by synthetic biology regulation.Microbial cell factories · 2026Article
- Engineered bacteria reprogram tumor microenvironmentActa pharmaceutica Sinica. B · 2026Article
- PEARL: Protein Eluting Alginate with Recombinant Lactobacilli.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
- Translational approaches in microbiome research: from functional mechanisms to next-generation therapeutics.Frontiers in microbiology · 2026Review
- The role of intestinal microbial metabolites in polycystic ovary syndrome: mechanistic insights and intervention prospects.Frontiers in endocrinology · 2026Review
- Design biology and mind-body health.Journal, genetic engineering & biotechnology · 2025Review
- The ladder of regulatory stringency and balance: an application to the US FDA's regulation of bacterial live therapeutics.Gut microbes · 2025Review
- Developing anACS pharmacology & translational science · 2025Article
- Engineering Useful Microbial Species for Pharmaceutical Applications.Microorganisms · 2025Review
- Engineering probiotic Escherichia coli for inflammation-responsive indoleacetic acid production using RiboJ-enhanced genetic circuits.Journal of biological engineering · 2025Article
- Engineered probiotics for inflammatory bowel disease therapy: mechanisms, delivery strategies, and precision medicine.Frontiers in microbiology · 2025Review
- Engineered bacteria as living therapeutics: Next-generation precision tools for health, industry, environment, and agriculture.AIMS microbiology · 2025Review
- Characterizing probiotic profiles using genomic and metabolomic insights into chicken cecum-derivedFrontiers in microbiology · 2025Article
- Genetically engineered bacteria as inflammatory bowel disease therapeutics.Engineering microbiology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The past decade has seen growing interest in bacterial engineering for therapeutically relevant applications. While early efforts focused on repurposing genetically tractable model strains, such as
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.